151.80Open151.80Pre Close0 Volume2 Open Interest450.00Strike Price0.00Turnover98.56%IV10.69%PremiumMay 16, 2025Expiry Date116.09Intrinsic Value100Multiplier16DDays to Expiry35.71Extrinsic Value100Contract SizeAmericanOptions Type-0.9146Delta0.0024Gamma2.83Leverage Ratio-0.2985Theta-0.1223Rho-2.59Eff Leverage0.1075Vega
Madrigal Pharmaceuticals Stock Discussion
Can Madrigal's Rezdiffra Breakthrough in Cirrhosis Patients Transform Liver Disease Treatment?
📊⚡️📊
MDGL gained as much as 15.2% to a $294.44 intraday high after Wolfe lauded the company's breakthrough liver drug Rezdiffra, according to published reports.
The U.S. Food and Drug Administration approved Rezdiffra in March as the first treatment fornonalcoholic steatoh...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$